Ocular Therapeutix Advances OTX-TKI Phase 3 Trials for Wet AMD with Novel 9-Month Sustained Release Platform
核心洞察
Ocular Therapeutix is conducting two Phase 3 clinical studies (SOL-1 and SOL-R) evaluating OTX-TKI (Axpaxli), a novel tyrosine kinase (搜索) inhibitor delivered through a proprietary hydrogel platform for wet age-related macular degeneration (搜索).
The SOL-1 superiority study compares a single injection of Axpaxli versus Eylea in treatment-naive patients, with primary outcomes at 9 months and results expected in Q1 2026.
OTX-TKI offers sustained drug release lasting up to 9 months through a 25-gauge intravitreal injection, with the polymer disappearing as the drug is depleted to provide clear re-dosing guidance.
Ocular Therapeutix is advancing two Phase 3 clinical trials for OTX-TKI (Axpaxli), a novel sustained-release treatment for wet age-related macular degeneration (搜索) that could transform patient care by extending dosing intervals to up to 9 months. The innovative therapy combines axitinib, a tyrosine kinase (搜索) inhibitor, with the company's proprietary hydrogel platform to deliver prolonged drug release through a single intravitreal injection.
Dual Phase 3 Strategy Targets Superior Efficacy and Commercial Viability
The company is conducting two distinct Phase 3 studies—SOL-1 and SOL-R—designed to provide both regulatory approval and commercially relevant data for physicians. According to Peter Kaiser, MD, Chief Development Officer at Ocular Therapeutix, this approach differs from traditional pharmaceutical development where companies typically conduct two identical Phase 3 studies.
The SOL-1 study represents a superiority trial evaluating treatment-naive wet macular degeneration (搜索) patients who receive a single injection of Axpaxli versus Eylea, with follow-up for 9 months and primary outcomes measured at 9 months. Results are expected in the first quarter of 2026. Kaiser emphasized that proving superiority rather than non-inferiority could provide significant advantages, including pricing benefits and elimination of step therapy requirements imposed by many U.S. insurance companies.
The SOL-R study takes a different approach as a non-inferiority trial, comparing Axpaxli administered every 6 months versus Eylea delivered every 8 weeks. This design allows evaluation of fixed 6-month dosing intervals, leveraging the drug's 9-month duration to potentially maintain the majority of patients on a consistent dosing schedule. The SOL-R study is expected to read out approximately one year after SOL-1.
Novel Mechanism and Delivery Platform
OTX-TKI functions as a pan-VEGF inhibitor, blocking downstream activation of all three VEGF receptors (搜索) through tyrosine kinase (搜索) inhibition. The drug is delivered through Ocular Therapeutix's proprietary hydrogel platform, which enables zero-order kinetics drug release starting immediately and lasting up to 9 months.
The treatment is administered as a single intravitreal injection through a 25-gauge needle in an office setting, distinguishing it from existing long-duration treatments that require surgical procedures. Kaiser noted that while two FDA-approved long-duration products exist—the port delivery system and the Neurotech Pharmaceuticals (搜索) device recently approved for MacTel (搜索)—both require surgical implantation.
Unique Polymer Design Provides Clinical Guidance
A key innovation in OTX-TKI's design is the polymer's disappearance timeline, which coincides with drug depletion. Kaiser explained that the polymer disappears at 9 months with a final release of free drug, allowing retina specialists to visually confirm when the treatment remains active. This contrasts with existing polymers like those in Ozurdex, where the implant may remain visible in the eye long after drug release has ended.
"If you see the polymer in the eye, you know it's still there," Kaiser stated. "As it disappears, the drug disappears. Now you know it's time to reinject." This design feature addresses a significant clinical challenge in determining optimal re-dosing timing for sustained-release therapies.
First Potential TKI Approval in Ophthalmology
While tyrosine kinase (搜索) inhibitors have achieved significant success in oncology with multiple FDA-approved products, no TKI has received FDA approval for ophthalmological applications. Various companies are exploring TKI delivery through eye drops and systemic administration, but Ocular Therapeutix believes local delivery through their hydrogel platform represents the optimal approach for managing macular degeneration (搜索) and diabetic eye disease (搜索).
The company's strategy focuses on sustained local delivery lasting 6 to 12 months, which Kaiser described as "a sweet spot for what retina specialists want" in treating these chronic conditions that typically require frequent injections with current standard-of-care therapies.